GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ICARES Medicus Inc (ROCO:6612) » Definitions » Valuation Rank

ICARES Medicus (ROCO:6612) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is ICARES Medicus Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


ICARES Medicus Valuation Rank Related Terms

Thank you for viewing the detailed overview of ICARES Medicus's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


ICARES Medicus Business Description

Traded in Other Exchanges
N/A
Address
Number 16, Sec.2, Sheng Yi Road, 4th Floor, Hsinchu County, Zhubei, TWN, 30261
ICARES Medicus Inc is engaged in providing high-grade nanomedical lubricious coatings and various surface treatments for implantable or interventional medical devices and designing, developing, manufacturing and sale of intraocular lenses and nanomedical devices. Its products include Artificial Lens. The Company manages segments based on geography, and divides segments into the R.O.C segment, the China segment, and the U.S.A segment. It earns the majority of its revenue from U.S.A. segment.